TOPRA Annual Veterinary Symposium Introduction to the Case Study A presentation by Lesley Reeve, Module leader.

Slides:



Advertisements
Similar presentations
© 2004 by Thomson Delmar Learning, a part of the Thomson Corporation. Fundamentals of Pharmacology for Veterinary Technicians Chapter 2 Veterinary Drug.
Advertisements

Pre-clinical and Clinical Regulatory Overview
EPAA Annual conference November Regulatory acceptance of alternative approaches for pharmaceuticals Jean-Marc Vidal Safety & Efficacy of Human Medicines.
PH: March 2, TASKSPerson in Charge and Deadlines Research Design Data Collection Techniques Plan for Data Collection Cognitive Drug Research Assessment.
Marc Bailie DVM, PhD Director In Vivo Facility Michigan State University, Chief Development Officer Integrated Nonclinical Development Solutions (INDS)
Single-Patient Use of Investigational Drugs and Biologic Products for Treating Cancer Grant Williams, M.D. Medical Team Leader DODP/CDER/FDA.
How Do I Get Into Phase 1 Trials With My Compound?
1 Pharmacology/Toxicology information to submit an IND for an anticancer drug.
1 Everything You Wanted to Know About GLPs…. but were afraid to ask Janet Rose Christensen, M.S.P.H. Vice President, Regulatory Affairs and Quality AVI.
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH Working with FDA: Biological Products and Clinical Development Critical Path.
Genomics Commercialization Glen Schuler Managing Director, Industry Liaison Office University of Saskatchewan.
DRUG SAFETY RESEARCH June 16, ISSUES Pharmaceutical Industry Depends on Block Buster Model (currently ~80 BBs). Block Buster Model requires fast.
Regulatory and Industry Requirements for Botanical Drug Products Prof. Dr. Basavaraj K. Nanjwade M. Pharm., Ph. D Department of Pharmaceutics KLE University.
Stefan Franzén Introduction to clinical trials.
Toxicology in Drug Development
+ Drug Development and Review Process. + Objectives Learn the processes involved in drug discovery and development Define the phases involved in FDA drug.
Neonatal/Juvenile Animal Safety Studies Kenneth L. Hastings, Dr.P.H., D.A.B.T. Office of New Drugs, CDER.
Food and Drug Administration Preclinical safety data for “first in human” (FIH) clinical trials in healthy volunteer subjects Oncology Drug Advisory Committee.
Training Workshop on Pharmaceutical Development with a Focus on Paediatric Medicines / October |1 | Regulatory Requirement on Dossier of Medicinal.
CDER IND/NDA Reviews Guidance, The Common Technical Document and Good Review Practice John K. Leighton, Ph.D., DABT CDER/FDA.
Stages of drug development
Guidance for Industry M4S: The CTD-Safety
Good Clinical Practice (GCP)- An introduction Dr Noor Ibrahim Mohamed Sakian.
IND-Enabling Safety Studies for Rare Diseases
Justina A. Molzon, MS Pharm, JD
Cellular Products for Cardiac Diseases Dwaine Rieves, MD Center for Biologics Evaluation and Research FDA Perspective on:
Nonclinical Studies Subcommittee Advisory Committee for Pharmaceutical Science CMC Issues for Screening INDs Eric B. Sheinin, Ph.D. Acting Deputy Director.
29/11/2007KLE University, Belgaum CURRENT PHARMACOLOGY & TOXICOLOGY GUIDLINES FOR PHARMACEUTICAL INDUSTRY Dr. Basavaraj K. Nanjwade M.Pharm., Ph.D.
Essential Considerations for Your IND Submission: Objectives and Pitfall Avoidance in Your Preclinical Program Darren Warren.
Phase 1 Clinical Studies First-In-Human (FIH) Pharmacologically-Guided Dose Escalation Jerry M. Collins, Ph.D. Developmental Therapeutics Program Division.
Clinical Trial Review and Approval: New Regulations and their implications Siddika Mithani, Ph.D Clinical Trials & Special Access Programme Therapeutic.
Drug Development Lynnda Reid, Ph.D. Pharmacology/Toxicology Reviewer
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.
Reproductive Health Drugs, Pregnancy Labeling Subcommittee Meeting March 28-29, 2000 Holli A. Hamilton, M.D., M.P.H. Pregnancy Labeling Team Office of.
Nonclinical Perspective on Initiating Phase 1 Studies for Small Molecular Weight Compounds John K. Leighton, PH.D., DABT Supervisory Pharmacologist Division.
DETERMINATION OF RELATED SUBSTANCES & IMPURITIES IN DRUGS BY ICH GUIDE LINES BY M.PAUL RICHARDS.
(Dr). Santosh Kumar Narla, Formulation Regulatory Affairs,
MAIN TOXICITY TESTING. TESTING STRATEGIES A number of different types of data are used in order to establish the safety of chemical substances for use.
The New Drug Development Process (www. fda. gov/cder/handbook/develop
Predictive safety study of ticagrelor's degradation combining LC-MS and in silico approach H. SADOU YAYE*, B. DO, N. YAGOUBI * Pharmacist at Pitié-Salpêtrière.
1 FDA Guidance for Industry: ANDAs: Impurities in Drug Substances Published by US FDA’s Center for Drug Evaluation and Research June 2009.
Applicability of Existing Regulations to the Development of a Dendrimer Nanotechnology-Based Pharmaceutical Presentation to Advisory Committee for Pharmaceutical.
1 Operation of the Prescription Drug User Fee Program Janet Woodcock, M.D. Deputy Commissioner for Operations November 14, 2005.
Chapter 2 Veterinary Drug Development and Control
UPDATE: Nonclinical Reproductive Toxicity Information in Assessing Human Risk Joseph J. DeGeorge Ph.D. Associate Director for Pharmacology and Toxicology.
Overview of Drugs and Biologics Dr Léo Bouthillier, Therapeutic Products Directorate & Dr Omar Tounekti, Biologics and Genetic Therapies Directorate Health.
Role of VICH and VICH guidelines in the approval process for veterinary medicinal products David Mackay, European Medicines Agency VICH Workshop – Dar.
ENABLING AND PROMOTING EXCELLENCE IN THE HEALTHCARE REGULATORY PROFESSION TOPRA Nonclinical Development Module Non-clinical studies in drug development.
E-Clinical
Introduce GLP/GCP into China Shixin XU, PhD, Prof. China IVDC.
httpwww.youtube.com/watch?v=DhxD6sVQEYc:// The Drug Discovery Process.
Cancer Clinical Trials Office Clinical Trials & Research Training Oct2014.
Pharmacology/Toxicology in the Investigator Brochure
for Human Pharmaceuticals Kyung-Chul Choi D.V.M., Ph.D.
Mutagenic Impurities: Guidances Update w/ CMC Perspectives
Regulatory– Terms & Definitions רגולציה - מונחים והגדרות
Pre-Investigational New Drug (pre-IND) Meeting with FDA
Nonclinical Information in the Common Technical Document: Opportunities for Content Reuse Peggy Zorn, MPI Research Susan Mattano, Pfizer, Inc.

Susan Makris U.S. EPA, Office of Research and Development
Regulatory Perspective
The Lifecycle of Pharmaceutical products
Drug design and testing,

Suzanne M. Sensabaugh, MS, MBA
Dose setting for a Phase I Clinical Study
Pharmaceuticals Industry
Quality guidelines on impurities
Aparna Raychaudhuri, Ph. D
VICH GL 54, Studies to evaluate the safety of residues of veterinary drugs in human food: General approach to establish an Acute Reference Dose (ARfD)
Presentation transcript:

TOPRA Annual Veterinary Symposium Introduction to the Case Study A presentation by Lesley Reeve, Module leader

 Timing  Run over 2 days  Start 16:20 today (up to 2.5 hours), continued tomorrow (1 hour)  Structure  Part A - Approaches to support clinical development stages (FIM, Phase II/III and marketing) [~45 min]  Part B – New impurities during scale up [~30 min]  Part C – Major human metabolite [~30 min] Case Study Introduction

Study design:  Endpoint (pharmacology, safety pharmacology, kinetics, general toxicity, genetic toxicity, reproductive / developmental toxicity, carcinogenicity, other toxicities)  Species (rodent & non-rodent)  Duration of the studies Case Study - Considerations

 The Lectures!  ICH M3 Guideline on “Nonclinical Safety studies for the conduct of human clinical trials for Pharmaceuticals”  ICH ‘S’ (safety) guidelines  ICHQ3A & Q3B & ICH M7 (guidance on impurities)  FDA “Guidance for Industry, Safety Testing of Drug Metabolites”  ICH M3 Q&A document. Case Study – Useful References

QUESTIONS?

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2024 SlidePlayer.com. Inc. All rights reserved.